Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme
Open Access
- 29 March 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-20
Abstract
Malignant gliomas are a type of primary brain tumour that originates in glial cells. Among them, glioblastoma multiforme (GBM) is the most common and the most aggressive brain tumour in adults, classified as grade IV by the World Health Organization. The standard care for GBM, known as the Stupp protocol includes surgical resection followed by oral chemotherapy with temozolomide (TMZ). This treatment option provides a median survival prognosis of only 16–18 months to patients mainly due to tumour recurrence. Therefore, enhanced treatment options are urgently needed for this disease. Here we show the development, characterization, and in vitro and in vivo evaluation of a new composite material for local therapy of GBM post-surgery. We developed responsive nanoparticles that were loaded with paclitaxel (PTX), and that showed penetration in 3D spheroids and cell internalization. These nanoparticles were found to be cytotoxic in 2D (U-87 cells) and 3D (U-87 spheroids) models of GBM. The incorporation of these nanoparticles into a hydrogel facilitates their sustained release in time. Moreover, the formulation of this hydrogel containing PTX-loaded responsive nanoparticles and free TMZ was able to delay tumour recurrence in vivo after resection surgery. Therefore, our formulation represents a promising approach to develop combined local therapies against GBM using injectable hydrogels containing nanoparticles.Keywords
Funding Information
- Trinity College Dublin (Postgraduate Ussher Fellowship, School of Pharmacy and Pharmaceutical Sciences)
- Horizon 2020 Framework Programme (952259)
- H2020 European Research Council (758887)
- Wellcome Trust (Institutional Strategic Support Fund)
This publication has 59 references indexed in Scilit:
- Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Cancers, 2013
- A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain TissueScience Translational Medicine, 2012
- Mesoporous Silica Nanoparticles End‐Capped with Collagen: Redox‐Responsive Nanoreservoirs for Targeted Drug DeliveryAngewandte Chemie International Edition, 2010
- Biocompatibility, Biodistribution, and Drug‐Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in AnimalsSmall, 2010
- Combination of Intracranial Temozolomide With Intracranial Carmustine Improves Survival When Compared With Either Treatment Alone in a Rodent Glioma ModelNeurosurgery, 2010
- Determination of quantitative parameters of Escherichia coli phagocytosis by mouse peritoneal macrophagesCell and Tissue Biology, 2007
- A Reliable Tool to Determine Cell Viability in Complex 3-D Culture: The Acid Phosphatase AssaySLAS Discovery, 2007
- Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer CellsNanoBiotechnology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Pharmacokinetics of the Carmustine ImplantClinical Pharmacokinetics, 2002